Writing on nanomedicine reproducibility, biological design standards, SBOL3, and regulatory science. Published as the work develops.
Biological surveillance does not primarily suffer from a shortage of data. It suffers from an inability to make data generated across different biological domains function as a coherent system.
Read insight →The instinct to treat biological design data as proprietary is understandable. It is also strategically wrong. Open standards do not erode competitive advantage — they create the conditions in which competitive advantage is possible.
LNPs are the most clinically consequential nanoparticle platform in the world right now. The gap between how far the science has come and how poorly we document it is wider than it has ever been.
The fastest vaccine development in history also revealed, in stark detail, the infrastructure failures that structured biological design data would have reduced. This is the case study the field needs to examine honestly.
A formal, layered architecture for describing nanoparticle therapeutic systems as structured, reproducible, and regulatory-ready data objects.
The life sciences are building at a scale and complexity that informal documentation can no longer support. A shared design language is not optional infrastructure — it is the foundation on which reproducible, translatable, and safe nanomedicine depends.
The reproducibility challenges in nanomedicine are routinely framed as a scientific limitation. Increasingly, both academic literature and industrial experience suggest that this framing is incomplete. In most cases, the underlying problem is not the science. It is the way designs are described — and that is a problem the field has the tools to fix right now.